<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>, the neurohormone arginine vasopressin (AVP) may act primarily through V1a and V1b receptors, which promote vasoconstriction, <z:mp ids='MP_0010633'>myocardial hypertrophy</z:mp>, and release of adrenocorticotropic hormone </plain></SENT>
<SENT sid="1" pm="."><plain>The preanalytical instability of AVP limits the investigation of whether this hormone associates with cardiovascular events, but the stable <z:chebi fb="0" ids="24396">glycopeptide</z:chebi> copeptin may serve as a surrogate because it is co-secreted with AVP from the posterior pituitary </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we studied whether copeptin predicts cardiovascular risk and mortality in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We measured copeptin at baseline in 1241 hemodialysis patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> participating in the German <z:mp ids='MP_0002055'>Diabetes</z:mp> and Dialysis Study </plain></SENT>
<SENT sid="4" pm="."><plain>The median copeptin level was 81 pmol/L (interquartile range, 81 to 122 pmol/L) </plain></SENT>
<SENT sid="5" pm="."><plain>In Cox regression analyses, compared with patients with copeptin levels in the lowest quartile (â‰¤51 pmol/L), patients with copeptin levels in the highest quartile (&gt;122 pmol/L) had a 3.5-fold increased risk for <z:hpo ids='HP_0001297'>stroke</z:hpo> (HR, 3.48; 95% CI: 1.71 to 7.09), a 73% higher risk for <z:hpo ids='HP_0001699'>sudden death</z:hpo> (HR, 1.73; 95% CI: 1.01 to 2.95), a 42% higher risk for combined cardiovascular events (HR, 1.42; 95% CI: 1.06 to 1.90), and a 48% higher risk for <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality (HR, 1.48; 95% CI: 1.15 to 1.90) </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, we did not detect significant associations between copeptin levels and risks for <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> or <z:hpo ids='HP_0011420'>death</z:hpo> caused by <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>In conclusion, copeptin levels strongly associate with <z:hpo ids='HP_0001297'>stroke</z:hpo>, <z:hpo ids='HP_0001699'>sudden death</z:hpo>, combined cardiovascular events, and mortality in hemodialysis patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>Whether vasopressin receptor <z:chebi fb="68" ids="48706">antagonists</z:chebi> will improve these outcomes requires further studies </plain></SENT>
</text></document>